CDKN2B and neoplasm: Among them, cyclin dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B‐AS1), a lncRNA initially identified in a genome‐wide association study of type 2 diabetes and cardiovascular diseases,20 has been proposed as a promising therapeutic target or prognostic marker for various malignancies, as it is aberrantly expressed in diverse types of tumours.21